Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 10/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24021873 | 0.90 | HRH3 (0.43) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL20128707 | 0.81 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL20325651 | 0.79 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL24654227 | 0.79 | CHRNB4 (0.42) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL14944847 | 0.76 | CARM1 (0.53) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL20317557 | 0.75 | KDM4E (0.44) | HRH3 | |
| SCHEMBL21025871 | 0.73 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL20128699 | 0.71 | HRH3 (0.43) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL21906886 | 0.70 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL20812669 | 0.70 | ALDH1A1 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | SLC6A2 4744/4885SLC6A4 4819/4885SLC6A3 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.